myelodysplastic syndromes (MDS) | Page 17 | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure

Author(s): 
Mossner M, Jann JC, Wittig J, Nolte F, Fey S, Nowak V, Obländer J, Pressler J, Palme I, Xanthopoulos C, Boch T, Metzgeroth G, Röhl H, Witt SH, Dukal H, Klein C, Schmitt S, Gelß P, Platzbecker U, Balaian E, Fabarius A, Blum H, Schulze TJ, Meggendorfer M
Primary Author: 
Mossner M
Journal Title: 
Blood
Original Publication Date: 
Jun 2016

Clonal evolution is believed to be a main driver for progression of various types of cancer and implicated in facilitating resistance to drugs.

Bone Marrow Diseases: 

Pexmetinib: a novel dual inhibitor of Tie-2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia

Author(s): 
Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S, Bhagat T, Bhattacharyya S, Assal A, Shastri A, Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garr
Primary Author: 
Bachegowda L
Journal Title: 
Cancer Res.
Original Publication Date: 
Jun 2016

Bone Marrow Diseases: 

Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes

Author(s): 
Nazha A, Narkhede M, Radivoyevitch T, Seastone DJ, Patel BJ, Gerds AT, Mukherjee S, Kalaycio M, Advani A, Przychodzen B, Carraway HE, Maciejewski JP, Sekeres MA
Primary Author: 
Nazha A
Journal Title: 
Leukemia
Original Publication Date: 
Jun 2016

The Revised

Bone Marrow Diseases: 

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

Author(s): 
Santini V, Almeida A, Giagounidis A, Gröpper S, Jonasova A, Vey N, Mufti GJ, Buckstein R, Mittelman M, Platzbecker U, Shpilberg O, Ram R, Del Cañizo C, Gattermann N, Ozawa K, Risueño A, MacBeth KJ, Zhong J, Séguy F, Hoenekopp A, Beach CL, Fenaux P
Primary Author: 
Santini V
Journal Title: 
J Clin Oncol
Original Publication Date: 
Jun 2016

PURPOSE:

Bone Marrow Diseases: 

Raleigh

Thank you for attending the 2016 Raleigh Patient and Family Conference. Below you will find copies of all the presentations.

Event Date: 
Sat, 07/16/2016 - 8:00am
Conference Event Type: 

Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and po

Author(s): 
Garcia-Manero G, Almeida A, Giagounidis A, Platzbecker U, Garcia R, Voso MT, Larsen SR, Valcarcel D, Silverman LR, Skikne B, Santini V
Primary Author: 
Garcia-Manero G
Journal Title: 
BMC Hematol
Original Publication Date: 
May 2016

BACKGROUND:

Bone Marrow Diseases: 

Association between Transfusion Status and Overall Survival in Patients with Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis

Author(s): 
Harnan S, Ren S, Gomersall T, Everson-Hock ES, Sutton A, Dhanasiri S, Kulasekararaj A
Primary Author: 
Harnan S
Journal Title: 
Acta Haematol
Original Publication Date: 
Apr 2016

INTRODUCTION:

Multiple studies show that transfusion independence (TI) in myelodysplastic syndrome (MDS) has a positive impact on overall survival (OS). To assess this, a systematic review and meta-analysis of the association between TI and OS in patients with MDS was conducted (PROSPERO ID: CRD42014007264).

Bone Marrow Diseases: